Shirine Voller

Active vaccine safety surveillance: Experience from a prospective cohort event monitoring study of COVID-19 vaccines in Kenya.Odhiambo DB Akech D Karia B Kimani M Sang S Sigilai A Voller S Mataza C Mang'ong'o D Jalang'o R Mandale M Etyang AO Scott JAG Agweyu A Kagucia EW
PLOS Glob Public Health, (2025). 5:e0005080

Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration.Kagucia EW Voller S Ziraba AK Bigogo G Munywoki PK Makobu K Nokes DJ Nyagwange J Orlendo C Akech D Sigilai A Onyango C Juma B Herman-Roloff A Munyua P Apondi C Lidechi S Audi A Ouma A Aol G Misore T Nasimiyu C Onyango D Lo T Kasera K Jalang'o R Kingwara L Adetifa I Etyang AO Warimwe G Agweyu A Scott JAG
Gates Open Res, (2025). 8:60

SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.Kagucia EW Ziraba AK Nyagwange J Kutima B Kimani M Akech D Ng'oda M Sigilai A Mugo D Karanja H Gitonga J Karani A Toroitich M Karia B Otiende M Njeri A Aman R Amoth P Mwangangi M Kasera K Ng'ang'a W Voller S Ochola-Oyier LI Bottomley C Nyaguara A Munywoki PK Bigogo G Maitha E Uyoga S Gallagher KE Etyang AO Barasa E Mwangangi J Bejon P Adetifa IMO Warimwe GM Scott JAG Agweyu A
Influenza Other Respir Viruses, (2023). 17:e13173

SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021.Etyang AO Adetifa I Omore R Misore T Ziraba AK Ng'oda MA Gitau E Gitonga J Mugo D Kutima B Karanja H Toroitich M Nyagwange J Tuju J Wanjiku P Aman R Amoth P Mwangangi M Kasera K Ng'ang'a W Akech D Sigilai A Karia B Karani A Voller S Agoti CN Ochola-Oyier LI Otiende M Bottomley C Nyaguara A Uyoga S Gallagher K Kagucia EW Onyango D Tsofa B Mwangangi J Maitha E Barasa E Bejon P Warimwe GM Scott JAG Agweyu A
PLOS Glob Public Health, (2022). 2:e0000883

"We should be at the table together from the beginning": perspectives on partnership from stakeholders at four research institutions in sub-Saharan Africa.Voller S Chitalu CM Nyondo-Mipando AL Opobo T Bangirana CA Thorogood N Schellenberg J Chi P
Int J Equity Health, (2022). 21:111

Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya.Etyang AO Lucinde R Karanja H Kalu C Mugo D Nyagwange J Gitonga J Tuju J Wanjiku P Karani A Mutua S Maroko H Nzomo E Maitha E Kamuri E Kaugiria T Weru J Ochola LB Kilimo N Charo S Emukule N Moracha W Mukabi D Okuku R Ogutu M Angujo B Otiende M Bottomley C Otieno E Ndwiga L Nyaguara A Voller S Agoti CN Nokes DJ Ochola-Oyier LI Aman R Amoth P Mwangangi M Kasera K Ng'ang'a W Adetifa IMO Wangeci Kagucia E Gallagher K Uyoga S Tsofa B Barasa E Bejon P Scott JAG Agweyu A Warimwe GM
Clin Infect Dis, (2022). 74:288-293

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya.Kagucia EW Gitonga JN Kalu C Ochomo E Ochieng B Kuya N Karani A Nyagwange J Karia B Mugo D Karanja HK Tuju J Mutiso A Maroko H Okubi L Maitha E Ajuck H Mukabi D Moracha W Bulimu D Andanje N Aman R Mwangangi M Amoth P Kasera K Ng'ang'a W Nyaguara A Voller S Otiende M Bottomley C Agoti CN Ochola-Oyier LI Adetifa IMO Etyang AO Gallagher KE Uyoga S Barasa E Bejon P Tsofa B Agweyu A Warimwe GM Scott JAG Magarini Sub-County Tda Sars-CoV-2 Serosurveillance Team The Busia County TDASars-CoV-Serosurveillance Team
Open Forum Infect Dis, (2021). 8:ofab314

Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.Adetifa IMO Uyoga S Gitonga JN Mugo D Otiende M Nyagwange J Karanja HK Tuju J Wanjiku P Aman R Mwangangi M Amoth P Kasera K Ng'ang'a W Rombo C Yegon C Kithi K Odhiambo E Rotich T Orgut I Kihara S Bottomley C Kagucia EW Gallagher KE Etyang A Voller S Lambe T Wright D Barasa E Tsofa B Bejon P Ochola-Oyier LI Agweyu A Scott JAG Warimwe GM
Nat Commun, (2021). 12:3966

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.Uyoga S Adetifa IMO Karanja HK Nyagwange J Tuju J Wanjiku P Aman R Mwangangi M Amoth P Kasera K Ng'ang'a W Rombo C Yegon C Kithi K Odhiambo E Rotich T Orgut I Kihara S Otiende M Bottomley C Mupe ZN Kagucia EW Gallagher KE Etyang A Voller S Gitonga JN Mugo D Agoti CN Otieno E Ndwiga L Lambe T Wright D Barasa E Tsofa B Bejon P Ochola-Oyier LI Agweyu A Scott JAG Warimwe GM
Science, (2021). 371:79-82

Serosurveillance for SARS-CoV-2 Antibodies in a cohort of Health Care Workers in Kenya..Etyang AO Lucinde R Gitonga JN Kalu C Karani A Nyagwange J Mugo D Karanja HK Tuju J Mutiso A Maroko H Okubi L Maitha E Mukabi D The HCW SARS-CoV-2 Serosurveillance Team, Aman R Mwangangi M Amoth P Kasera K NgÔÇÖangÔÇÖa W Nyaguara A Voller S Otiende M Bottomley C Agoti CN Ochola-Oyier LI Adetifa IMO Gallagher KE Uyoga S Barasa E Bejon P Tsofa B Agweyu A Warimwe GM Scott JAG
1st International Conference on Public Health in Africa (CPHIA), (2021). :

High anti-SARS-CoV-2 IgG antibody seroprevalence among long-distance trucking crews in Kenya within one year of the COVID-19 pandemic..Kagucia EW Gitonga JN Kalu C Kuya N Ochieng B Karia B Ochomo E Karani A Nyagwange J Mugo D Karanja HK Tuju J Mutiso A Maroko H Okubi L Maitha E Mukabi D The TDA SARS-CoV-2 Serosurveillance Team Aman R Mwangangi M Amoth P Kasera K NgÔÇÖangÔÇÖa W Nyaguara A Voller S Otiende M Bottomley C Agoti CN Ochola-Oyier LI Adetifa I MO Etyang AO Gallagher KE Uyoga S Barasa E Bejon P Tsofa B Agweyu A Warimwe GM Scott JAG
1st International Conference on Public Health in Africa (CPHIA), (2021). :

Prevalence of anti-SARS-CoV-2 IgG antibodies among Kenyan blood donors between June and August 2021..Uyoga S Otiende M Adetifa IMO Karanja HK Gitonga J Mugo D Makale J Tawa B Singilai A Nyagwange J Tuju J Aman R Mwangangi M Amoth P Kasera K NgÔÇÖangÔÇÖa W Kilonzo N Chege E Yegon C Rotich T Orgut I Kagucia EW Gallagher KE Etyang A Voller S Bottomley C Lambe T Wright D Tsofa B Mwangangi J Barasa E Bejon P Ochola-Oyier LI Warimwe GM Scott JAG Agweyu A
1st International Conference on Public Health in Africa (CPHIA), (2021). :